Buscar resultados de ensayos clínicos
Bone Cysts - 25 Studies Found
Estado | Estudiar |
Enrolling by invitation |
Nombre del estudio: Osteoconduction Potential of an Injectable Calcium Phosphate in Orthopaedic Surgery in Fillings of Osseous Defects Condición: Grafting, Bone Fecha: 2005-09-12 Intervenciones: Device: MBCP-Gel (tm) |
Completed |
Nombre del estudio: Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face Condición: Neoplastic Syndrome Fecha: 2007-06-20 Intervenciones: Drug: tazarotene Tazarotene is a member of the acetylenic class of retinoids. |
Completed |
Nombre del estudio: Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back Condición: Skin Carcinoma Fecha: 2008-10-31 Intervenciones:
|
Withdrawn |
Nombre del estudio: Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) Condición: Basal Cell Carcinoma Fecha: 2010-07-06 Intervenciones:
|
Recruiting |
Nombre del estudio: Familial Investigations of Childhood Cancer Predisposition Condición:
|
Completed |
Nombre del estudio: Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas (BCC) in Gorlin Syndrome Patients Condición: Basal Cell Nevus Syndrome Fecha: 2016-04-27 Intervenciones:
|
Recruiting |
Nombre del estudio: Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas Condición: Basal Cell Carcinoma Fecha: 2015-12-14 Intervenciones: Drug: Vismodegib Vismodegib 150 mgs po qd for 3 months |
Recruiting |
Nombre del estudio: A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma Condición:
|
Recruiting |
Nombre del estudio: Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS) Condición: Basal Cell Carcinoma in Basal Cell Nevus Syndrome Fecha: 2015-01-21 Intervenciones: Drug: SUBA-Itraconazole Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily. |
Active, not recruiting |
Nombre del estudio: Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma Condición:
|